Reviewed by MedNext Clinical Team
Bisoprolol is a highly cardioselective beta-1 adrenoceptor blocker with proven mortality benefit in heart failure with reduced ejection fraction (HFrEF). Alongside ACE inhibitors (or ARBs) and mineralocorticoid receptor antagonists, it forms part of the evidence-based triple therapy that underpins the neurohormonal model of heart failure management. It is also widely used for rate control in atrial fibrillation (AF) [1].
Mechanism and Selectivity
Beta-blockers competitively antagonise catecholamines at adrenoceptors. Bisoprolol is highly selective for the beta-1 receptor, found predominantly in cardiac tissue, with minimal activity at beta-2 receptors (bronchial and vascular smooth muscle). Its beta-1 selectivity makes it one of the safest beta-blockers when use in patients with mild-to-moderate asthma or COPD is unavoidable — though it remains relatively contraindicated in significant obstructive airway disease.
Heart Failure with Reduced Ejection Fraction
The CIBIS-II trial demonstrated that bisoprolol 10 mg daily significantly reduced all-cause mortality (by 34%), sudden cardiac death, and hospitalisation compared with placebo in patients with HFrEF [1]. This survival benefit is a class effect for carvedilol, metoprolol succinate, and bisoprolol — the three beta-blockers with proven mortality benefit in HFrEF.
Start Low, Go Slow
Initiating bisoprolol in acutely decompensated heart failure can worsen haemodynamics. Beta-blockers should be started only when the patient is euvolaemic and clinically stable. The starting dose in HFrEF is 1.25 mg once daily, doubled at intervals of no less than 2 weeks as tolerated, targeting 10 mg once daily. Heart rate, blood pressure, symptoms, and fluid status should be reassessed at each titration step.
Rate Control in Atrial Fibrillation
Beta-blockers are first-line for rate control in AF, particularly in patients with concurrent HFrEF. Bisoprolol slows conduction through the AV node, reducing ventricular rate at rest and during exercise. A resting heart rate target of 60–100 bpm is generally appropriate; more lenient targets (below 110 bpm) may be acceptable in asymptomatic patients. Bisoprolol is preferred over rate-limiting calcium channel blockers (verapamil, diltiazem) in patients with HFrEF, as calcium channel blockers have negative inotropic effects.
Bradycardia Monitoring
Excessive bradycardia (heart rate below 50–55 bpm) or symptomatic bradycardia (dizziness, syncope, fatigue) requires dose reduction or temporary interruption. Bisoprolol should not be abruptly discontinued in patients with ischaemic heart disease as this can precipitate rebound tachycardia, hypertension, and myocardial ischaemia. If stopping is necessary, taper the dose gradually over 1–2 weeks.
Contraindications and Cautions
- Asthma: Significant bronchospasm risk — contraindicated in moderate-to-severe asthma. Mild, well-controlled asthma may be acceptable with careful monitoring.
- Uncontrolled heart failure: Do not initiate during acute decompensation.
- Significant bradycardia or heart block: Contraindicated in second or third-degree AV block (without pacemaker protection).
- Severe peripheral arterial disease: May worsen symptoms of claudication or critical limb ischaemia [1].
References
- CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.